ClinicalTrials.gg
CompletedNCT02182453Updated Jul 18, 2014

Single Rising Oral Doses of BI 10773 in Healthy Male Volunteers

A Phase 1 interventional study of BI 10773 - single rising dose and Placebo in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to male participants aged 20 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-07-18.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
20 Years to 35 Years
Sex
Male
01

Study summary

Study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 10773 administered to healthy Japanese male subjects with single rising oral doses (1, 5, 10, 25, and 100 mg).

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 35 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male volunteers who meet the following criteria:

    • Without clinically remarkable findings or clinically evident complications based on their concurrent illness, past medical history, physical examination, vital signs (blood pressure, pulse rate, and body temperature), 12-lead , and laboratory test results
    • Age ≥20 and Age ≤35 years
    • (BMI) ≥18.0 and ≤25.0 kg/m2
    • Persons who are willing to participate in this trial and who give their written consent before study initiation in accordance with the Good Clinical Practice (GCP)

Exclusion criteria

Exclusion Criteria:

  • Any finding of the medical examination (including blood pressure, pulse rate, body temperature, and ) deviating from normal and of clinical relevance
  • Any evidence of a concomitant disease
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological, or hormonal disorders
  • Surgery of the gastrointestinal tract (except appendectomy)
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  • History of relevant orthostatic hypotension, fainting spells, or blackouts
  • Chronic or relevant acute infections
  • History of relevant allergy/ (including allergy to a drug or its )
  • Intake of drugs with a long half-life (≥24 hours) within at least one month or less than 10 half-lives of the respective drug before administration of the product or during the trial
  • Use of any drugs within 10 days before administration of the investigational product or during the trial
  • Participation in another trial with an investigational drug within four months before administration of the investigational product or during the trial
  • Smoker (>10 cigarettes or >3 cigars or >3 pipes/day)
  • Inability to refrain from smoking on trial days
  • Alcohol abuse
  • Drug abuse
  • Blood donation (100 mL or more) within four weeks before administration of the investigational product or during the trial
  • Excessive physical activities within one week before administration of the investigational product or during the trial
  • Basically, a patient with a laboratory value outside the reference range of the clinical site will be excluded form the study. However, if the principal investigator does not see any problem for the subject to enter the study based on the result of assessment of physical examination and other clinical examination, the subject will be able to participate in the study. In this regard, however, subjects who meet one of the following criteria will be excluded from the study:

    • FPG (Fasting plasma glucose) ≥110mg/dL
    • (estimated glomerular filtration rate) \<60
    • abnormal value of urinalysis
  • Inability to comply with dietary regimen of the study centre
  • A marked baseline prolongation of /QTc interval (e.g., repeated demonstration of a QTc interval >450 ms)
  • A history of additional risk factors for TdP (torsade de pointes) (e.g., heart failure, hypokalemia, family history of long QT syndrome)Samsung2014
  • Renal glucosuria or elevated urinary glucose levels at screening (>15 mg/dl)
  • Any abnormal finding in Kidney or patients who have history of renal disease
  • Any other clinical conditions that investigator or sub-investigator judges that the subject is ineligible for study participation
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
48 participants (actual)

Study arms

  • Experimental
    BI 10773 - single rising dose

    Drug: BI 10773 - single rising dose

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Number of patients with adverse events

    Time frame: Up to 7 days

  2. Number of patients with abnormal changes in laboratory parameters

    Time frame: Baseline, day 2-4 and day 7

  3. Number of patients with clinically significant changes in vital signs (blood pressure, pulse rate, and body temperature)

    Time frame: Baseline, day 1-4 and day 7

  4. Number of patients with clinical significant changes in 12-lead ECG (electrocardiogram)

    Time frame: Baseline, day 1-4 and day 7

  5. Assessment of tolerability on a 4-point scale

    Time frame: Day 4

Secondary outcomes

  1. Cmax (maximum concentration of the analyte in plasma)

    Time frame: Before and 10, 20, 30, 45 minutes and 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 24, 34, 48 72 hours after administration of study drug

  2. tmax (time from dosing to maximum concentration)

    Time frame: Before and 10, 20, 30, 45 minutes and 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 24, 34, 48 72 hours after administration of study drug

  3. AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)

    Time frame: Before and 10, 20, 30, 45 minutes and 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 24, 34, 48 72 hours after administration of study drug

  4. %AUCtz-∞ (the percentage of the AUC0-∞ that is obtained by extrapolation)

    Time frame: Before and 10, 20, 30, 45 minutes and 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 24, 34, 48 72 hours after administration of study drug

  5. AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)

    Time frame: Before and 10, 20, 30, 45 minutes and 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 24, 34, 48 72 hours after administration of study drug

  6. λz (terminal rate constant in plasma)

    Time frame: Before and 10, 20, 30, 45 minutes and 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 24, 34, 48 72 hours after administration of study drug

  7. t1/2 (terminal half-life of the analyte in plasma)

    Time frame: Before and 10, 20, 30, 45 minutes and 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 24, 34, 48 72 hours after administration of study drug

  8. MRTpo (mean residence time of the analyte in the body after po administration)

    Time frame: Before and 10, 20, 30, 45 minutes and 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 24, 34, 48 72 hours after administration of study drug

  9. CL/F (total clearance of the analyte in the plasma after extravascular administration)

    Time frame: Before and 10, 20, 30, 45 minutes and 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 24, 34, 48 72 hours after administration of study drug

  10. Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)

    Time frame: Before and 10, 20, 30, 45 minutes and 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 24, 34, 48 72 hours after administration of study drug

  11. Aet1-t2 (amount of analyte that is eliminated in urine from the time point t1 to time point t2)

    Time frame: 2 hours before and 0-2, 2-4, 4-6, 6-8, 8-12, 12-24, 24-34, 34-48, and 48-72 hours after administration of study drug

  12. fet1-t2 (fraction of analyte eliminated in urine from time point t1 to time point t2)

    Time frame: 2 hours before and 0-2, 2-4, 4-6, 6-8, 8-12, 12-24, 24-34, 34-48, and 48-72 hours after administration of study drug

  13. CLR,t1-t2 (renal clearance of the analyte from the time point t1 until the time point t2)

    Time frame: 2 hours before and 0-2, 2-4, 4-6, 6-8, 8-12, 12-24, 24-34, 34-48, and 48-72 hours after administration of study drug

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008 and a primary completion of Aug 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2014
First posted
Jul 8, 2014
Start
Jun 2008
Primary completionActual
Aug 2008
Last update
Jul 18, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02182453
Responsible party
Sponsor
First posted
Jul 8, 2014
Start date
Jun 2008
Primary completion
Aug 2008
Last update
Jul 18, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Empagliflozin

Start the discussion